Induction of airway progenitor cells via p63 and KLF11 by Rho-kinase inhibitor Y27632 in hTERT-human nasal epithelial cells.
CYP
Human nasal epithelial cells
KLF11
gap junctions
hTERT
p63
tight junctions
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
08
2018
accepted:
23
12
2018
entrez:
23
3
2019
pubmed:
23
3
2019
medline:
23
3
2019
Statut:
epublish
Résumé
Rho-kinase inhibitor Y27632, which is a factor in conditional reprogramming culture, induces airway progenitor clone formation. To investigate whether Y27632 enhances airway progenitor cells in nasal epithelium, primary cultures of HNECs transfected with human telomerase reverse transcriptase (hTERT-HNECs) were treated with Y27632. In TERT-HNECs treated with Y27632 for 5 days, upregulation of p63, gap junction molecules Cx26, Cx30, Cx43, cytochrome P450 enzymes CYP2C9, CYP2C18, CYP39A1, CYP4B1, CYP2G1P, CYP4Z1, and KLF families KLF10 and KLF11 were observed compared to the control. Downregulation of tight junction molecules claudin-4, -7, and -23 was observed. Circumfential submembrane F-actin was also induced. The functions of gap junctional intercellular communication (GJIC) and the epithelial barrier were upregulated. Knockdown of p63 by siRNAs of TAp63 or ΔNp63 inhibited Cx26, Cx43 and CYP2C18, and induced claudin-1, and -4. Knockdown of KLF11 prevented p63 expression and enhancement of the epithelial barrier function by Y27632. In nasal mucosal tissues from patients with allergic rhinitis (AR), localized alteration of p63, KLF11, RhoA, Cx30 and claudin-4 was observed. Treatment with Y27632 in long-term culture induced airway progenitor cells via KLF11 in p63-positive human nasal epithelium. Airway progenitor cells of nasal epithelium induced by Y27632 is important in understanding upper airway disease-specific characteristics.
Types de publication
Journal Article
Langues
eng
Pagination
599-611Déclaration de conflit d'intérêts
None.
Références
Gastroenterology. 2001 Sep;121(3):566-79
pubmed: 11522741
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):978-86
pubmed: 11923237
J Cell Sci. 2006 Nov 15;119(Pt 22):4617-22
pubmed: 17093266
Cell Tissue Res. 2007 Oct;330(1):63-74
pubmed: 17701057
J Allergy Clin Immunol. 2007 Dec;120(6):1279-84
pubmed: 17949801
J Allergy Clin Immunol. 2007 Dec;120(6):1233-44; quiz 1245-6
pubmed: 18073119
Br J Cancer. 2009 Sep 1;101(5):829-39
pubmed: 19707205
Am J Pathol. 2012 Feb;180(2):599-607
pubmed: 22189618
J Allergy Clin Immunol. 2012 Nov;130(5):1087-1096.e10
pubmed: 22840853
J Hepatol. 2013 Apr;58(4):763-70
pubmed: 23183531
Biomed Res Int. 2013;2013:947072
pubmed: 23509817
J Biol Chem. 2013 Jun 14;288(24):17745-58
pubmed: 23589285
PLoS One. 2014 Feb 12;9(2):e88683
pubmed: 24533135
Allergy. 2014 Nov;69(11):1540-9
pubmed: 25104359
J Membr Biol. 2015 Apr;248(2):327-36
pubmed: 25652184
Int Forum Allergy Rhinol. 2016 Jun;6(6):611-7
pubmed: 26919292
Am J Respir Cell Mol Biol. 2016 Sep;55(3):323-36
pubmed: 27144410
Exp Cell Res. 2016 Sep 10;347(1):232-40
pubmed: 27514999
J Tissue Eng Regen Med. 2018 Jan;12(1):e313-e317
pubmed: 28488809
Sci Rep. 2017 Sep 7;7(1):10935
pubmed: 28883651